Where Will Morgan Stanley Stock Be in 10 Years?
Morgan Stanley (NYSE:MS) share price has been on a tear,…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Income Statement | ||||||
Revenue | $19.8M | $31M | $31.5M | $7.3M | $8.5M | |
Gross Profit | $19.8M | $29.6M | $28.4M | $6.9M | $7.8M | |
Operating Income | -$110.7M | -$125.3M | -$122.6M | -$31.6M | -$21.1M | |
EBITDA | -$3.1M | -$117.1M | -$122.9M | -$28.6M | -$20.2M | |
Diluted EPS | -$0.46 | -$2.65 | -$2.47 | -$0.61 | -$0.42 |
Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $95.2M | $153.5M | $177M | $195M | $57.4M | |
Total Assets | $99.5M | $158.9M | $184.8M | $200.8M | $63.6M | |
Current Liabilities | $9.4M | $37.7M | $21.1M | $30.6M | $34.5M | |
Total Liabilities | $12.1M | $80.4M | $102.8M | $146.3M | $130.4M | |
Total Equity | $87.4M | $78.5M | $82M | $54.5M | -$66.7M | |
Total Debt | -- | $40.6M | $70.8M | $72.5M | $55.2M |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$112.7M | -$112.9M | -$114.7M | -$25.2M | -$19.5M | |
Cash From Investing | $105M | -$35M | $35.2M | $11.9M | -$1.1M | |
Cash From Financing | $30.9M | $120.1M | -$18.7M | $25.9M | -$1.9M | |
Free Cash Flow | -$115.1M | -$113.1M | -$115.9M | -$25.3M | -$20.6M |
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
In the current month, MRNS has received 1 Buy ratings 6 Hold ratings, and 0 Sell ratings. The MRNS average analyst price target in the past 3 months is $1.07.
According to analysts, the consensus estimate is that Marinus Pharmaceuticals share price will rise to $1.07 per share over the next 12 months.
Analysts are divided on their view about Marinus Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Marinus Pharmaceuticals is a Sell and believe this share price will drop from its current level to $0.30.
The price target for Marinus Pharmaceuticals over the next 1-year time period is forecast to be $1.07 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Marinus Pharmaceuticals is a Hold. 6 of 7 analysts rate the stock a Hold at this time.
You can purchase shares of Marinus Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Marinus Pharmaceuticals shares.
Marinus Pharmaceuticals was last trading at $0.55 per share. This represents the most recent stock quote for Marinus Pharmaceuticals. Yesterday, Marinus Pharmaceuticals closed at $0.54 per share.
In order to purchase Marinus Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Morgan Stanley (NYSE:MS) share price has been on a tear,…
If there is one industry that can be termed truly…
The last several years have seen a series of tech…
Market Cap: $3.4T
P/E Ratio: 118x
Market Cap: $3.4T
P/E Ratio: 37x
Market Cap: $3.2T
P/E Ratio: 36x
FTAI Aviation [FTAI] is up 9.81% over the past day.
New Oriental Education & Technology Group [EDU] is down 1.13% over the past day.
Guardant Health [GH] is up 4.5% over the past day.